It was assessed as a monotherapy in pretreated metastatic BRCA1/2-mutated breast cancer patients: 6/35 (17%) evaluable women experienced response, and median PFS approached to 3.9 months [57]. The gene discussed is BRCA1; the disease is breast cancer.